One possible explanation is that the efficacy of bevacizumab alone or combined with other agents differs among tumor types, such as transplantable tumors in mice, spontaneous tumors and tumors from patients, which exhibit different degrees of vessel abnormality and levels of VEGF protein [15]. The gene discussed is VEGFA; the disease is neoplasm.